Compare Citius Pharmaceuticals Inc (CTXR) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Orion Office REIT Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Orion Office REIT Inc trades at $2.18 (market cap $125.50M). The key difference: Orion Office REIT Inc is far larger — about 9.2× Citius Pharmaceuticals Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Orion Office REIT Inc for 33 Days on average.
| CTXR | ONL | |
|---|---|---|
Market Cap | $13.62M | $125.50M |
Volume | 132,438 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $3.00 |
52-Week Low | $0.48 | $1.93 |
Typical Hold Time | 17 Days | 33 Days |
Enterprise Value | $3.79M | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
ONL trades at $2.17, down 4.41% today, with a bearish technical signal from moving averages but bullish oscillators. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Valuation metrics include P/S of 0.88 and P/B of 0.2, suggesting potential undervaluation, while analyst consensus is split evenly between Buy and Hold ratings. Recent news highlights strategic portfolio repositioning and a declared $0.02 dividend for H2-26.
Outlook remains challenged by operational losses and high leverage, though deep asset discounts and strategic reviews may offer turnaround potential. Key risks include sustained negative margins, debt servicing pressures, and office sector headwinds. Investment appeal hinges on execution of repositioning efforts and margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
